the care pathway must include as little disruption as possible in order to promote therapeutic success and improve the quality of life perceived by patients. This must result, in a process of continuous improvement of organizations, in a reduction in access times to diagnostic techniques (for example to imaging equipment and innovative treatments) and, when the situation allows, in care close to the patient's place of life. The objective of this service consists in supporting up to 10 experimental sites selected by the institute and monitoring these establishments with a view to capitalizing on these experiences for generalization purposes.

phase 1: state of the art: carry out a documentary review, conduct interviews with 10 institutions with an organization, all or part, of the course considered innovative in the field of cancer with poor prognosis. Phase 2: support of experimental sites: diagnosis of experimental sites, support of experimental sites. Phase 3: capitalization. The details of the services to be carried out are set out in the special technical clauses (cctp)